Drug-eluting stents (DES) play an important role in preventing the progression of atheromatous disease. It minimizes the potential risks of heart attacks and strokes, due to blockage of blood supply through the artery. It is implanted in patients to prop open arteries and facilitate blood flow to and from the heart.
“The U.S. and Western Europe are presently estimated to account for more than 65% of the sales of drug eluting stents market. Relatively higher prevalence of cardiovascular problems contribute to the significant demand of these stents in these regions”.
Coronary Artery Diseases, Peripheral Artery Diseases are the two application of drug eluting stents covered in the scope of the study. Out of these two, the coronary artery segment accounts for a significantly larger revenue share. In terms of product type, the microporous stents hold a significant market share. Innovations in stent technology related to material, coating and platform are propelling the growth of drug eluting stents market. Additionally, the need for effective therapies that reduce the risk of complications such as inflation, restenosis, and thrombosis is accelerating the demand for drug eluting stents market.
Drug Eluting Stents Revenue Share, 2017
The detailed research study provides qualitative and quantitative analysis of the drug eluting stents market. The market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue as well as sales volume across regions and further, across all the major countries. The supply side analysis covers regional production volume and capacity analysis. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
The competitive analysis conducted narrates that the market is composed of several players. Some of the prominent competitors include QualiMed, B. Braun Melsungen AG, Arterius Limited (Arterius), Biosensors International Group, Ltd., Cook Medical Inc.(Cook), KYOTO MEDICAL PLANNING Co., Ltd., Elixir Medical Corporation, Biotronik SE & Co. KG, Abbott Laboratories (Abbott), Shanghai MicroPort Medical (MicroPort Scientific Corporation), TERUMO CORPORATION, Alvimedica, Boston Scientific Corporation, OrbusNeich Medical Company Limited (ORBUSNEICH), and Micell Technologies, Inc. among others. The Biolimus A9 is an eluting stent, which is manufactured by Biosensors International Group based in Singapore. It is known for reducing drug circulation in the bloodstream by minimizing systemic exposure. Ultimaster is another popular DES product launched by Terumo Corporation, which is among the key players of this industry and is headquartered in Tokyo, Japan. It is a cobalt chromium stent with an open cell design and has a drug dose of sirolimus.
Drug Eluting Stents Market - by Product Type
Drug Eluting Stents Market - by Material Type
Drug Eluting Stents Market - by Application
Market By Region